**CURRICULUM VITAE – JEFFREY R OLSEN, MD**

**Personal Information:**

**Present Position:** Assistant Professor in Radiation Oncology,

 University of Colorado School of Medicine, Denver, CO

**Education:**

2008 - 2012 Resident, Department of Radiation Oncology, Washington University School of Medicine and Barnes-Jewish Hospital, St. Louis, Missouri

2007 - 2008 Internal Medicine Internship, Department of Internal Medicine, MacNeal Hospital, Berwyn, Illinois

2003 - 2007 Awarded Doctor of Medicine degree, Washington University School of Medicine, St. Louis, Missouri

1999 - 2003 Awarded BS degrees in physics and bioengineering*,* University of Illinois at Urbana, Champaign, Illinois

**Academic Positions / Employment:**

2016-presentAssistant Professor in Radiation Oncology, University of Colorado School of Medicine, Aurora, CO

2012 –2015 Assistant Professor in Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri

**University and Hospital Appointments and Committees:**

2016-present Consulting Staff, Memorial Hospital, Colorado Springs, CO

2015 – 2015 Committee on Admissions, Washington University School of medicine,
St. Louis, MO.

2014 – 2015 Leader of Musculoskeletal Oncology Focus Group, Washington University School of Medicine, St. Louis, MO

2014 –2015 Director of Medical Education, Department of Radiation Oncology, Washington University School of Medicine,

 St. Louis, MO

2013 – 2015 Member of Radiation Oncology Cross-Functional Team, St. Louis, MO

2013 – 2015 Medical Reviewer in the Radiation Oncology Clinical Services (ROCS)

 Core Laboratory

2012 – 2015 Assistant Professor, Barnes/Jewish Hospital, St Louis, MO

2012 - 2015 Consulting Staff, St Louis Children’s Hospital, St Louis, MO

2012 – 2015 Consulting Staff, Barnes-Jewish St Peters Hospital, St Peters, MO

2012 – 2015 Barnes/Jewish West County Hospital, St Louis, MO

2012 – 2015 Consulting Staff, Christian Northeast Hospital, St. Louis, MO

**Medical Licensure and Board Certification:**

 **Medical Licensure:** State of Colorado – License No. DR.0056215

 **Board Certification:** Radiation Oncology, American Board of Radiology – June 2013

**Honors and Awards:**

2010 American Radium Society (ARS) Young Oncologist Essay Award

2012 Radiologic Society of North America (RSNA) Research & Education Foundation Roentgen Resident/Fellow Research Award

2013 American Society for Therapeutic Radiation Oncology (ASTRO) – abstract “Sequential Short Course Radiation and FOLFOX as Preoperative Therapy for Rectal Cancer: Favorable LC, PFS, and QOL at 2 Years” selected for discussion at Best of ASTRO Meeting

2014 American Society for Therapeutic Radiation Oncology (ASTRO) – abstract “Predictors of Radiotherapy-Related GI Toxicity from Anal Cancer DP-IMRT: Secondary Analysis of RTOG 0529” selected for discussion at Best of ASTRO Meeting

**Professional Societies and Organizations:**

 American College of Radiology

 American Society of Clinical Oncology

 American Society of Therapeutic Radiation Oncology and Biology

 Missouri Radiological Society

 Particle Therapy Co-Operative Group – North America

 Radiological Society of North America

 European Society for Radiotherapy & Oncology

 Reviewer: International Journal of Radiation Oncology•Biology•Physics

 Reviewer: Practical Radiation Oncology

 Reviewer: Radiotherapy & Oncology

**Invited Lectures:**

1. “Adaptive Radiotherapy Panel Discussion,” Invited presentation at American Radium Society, May 5, 2015, Kauai, HI.
2. “Radiotherapy for Rectal Cancer: How Does it Work? and Q&A,” Invited Speaker at Society of Nuclear Medicine and Molecular Imaging Annual Meeting. June 8, 2014, St. Louis, MO.
3. “Physician Experience with MR-Guided Radiation Therapy,” Presentation given at ViewRay Symposium: Initial Clinical Experience with MRI-Guided Radiation Therapy. ViewRay Symposium at 33rd ESTRO Conference. April 5, 2014, Vienna, Austria.
4. Speaker at “Imaging Educational Course: MRI Applications in Radiation Oncology”, AAPM 2013, Indianapolis, IN.

**Selected First and Senior Author Oral Presentations:**

1. “Online Adaptive MR Guided Stereotactic Body Radiation Therapy for the Treatment of Oligometastatic Disease of the Abdomen and Central Thorax: Characterization of Potential Advantages”. ASTRO 2015 annual meeting, San Antonio, TX.
2. “Matched Pair Analysis of Sequential Short Course Radiation Therapy and FOLFOX Chemotherapy as Preoperative Therapy for Rectal Cancer: Improved DFS Compared to Institutional Controls Favors Near-Total Neoadjuvant Therapy.” ASTRO 2015 annual meeting, San Antonio, TX.
3. “Clinical Implementation of Online MR-Guided Adaptive Radiotherapy for Abdominopelvic Malignancies.” ESTRO annual meeting, May 2015.
4. “Predictors of Radiotherapy-Related GI Toxicity from Anal Cancer DP-IMRT: Secondary Analysis of RTOG 0529.” ASTRO 2014 annual meeting, San Francisco, CA. *Selected for presentation at 2014 Best of ASTRO Meeting.*
5. “The Effect of High-Dose Stereotactic Body Radiation Therapy on Liver Function Utilizing the Child-Pugh Classification System.” American Radium Society Annual Meeting 2014. St. Thomas, VI.
6. “Sequential Short Course Radiation and FOLFOX as Preoperative Therapy for Rectal Cancer: Favorable LC, PFS, and QOL at 2 Years.” Oral presentation. ASTRO 2013 annual meeting, Atlanta, GA. *Selected for presentation at 2013 Best of ASTRO Meeting.*
7. “Prognostic utility of squamous cell carcinoma antigen in carcinoma of the cervix: correlation with pre-and post-treatment FDG-PET.” American Radium Society Annual Meeting2010, Cancun, Mexico.
8. “Comparison of three treatment schemes for lung SBRT.” ASTRO 2010, San Diego, California

**Peer Reviewed Publications** (\*indicates corresponding/senior authorship)**:**

1. Acharya S, Fischer-Valuck B, Kashani R, Parikh PJ, Yang D, Zhao T, Green O, Wooten H, Li H, Hu Y, Rodriguez V, Olsen LA, Robinson C, Michalski J, Mutic S, **Olsen JR\***. Online MR Image-Guided Adaptive Radiotherapy: First Clinical Applications. International Journal of Radiation Oncology Biology Physics. In Press.

1. Noel CE, Parikh PJ, Spencer CR, Green OL, Hu Y, Mutic S, **Olsen JR\***. Comparison of onboard low-field magnetic resonance imaging versus onboard computed tomography for anatomy visualization in radiotherapy. Acta Oncol. 2015 Epub Jul 24:1-9.
2. Du L, DeFoe M, Ruzinova MB, **Olsen JR**, Wang-Gillam A. Perioperative Therapy for Surgically Resectable Pancreatic Adenocarcinoma. Hematol Oncol Clin North Am. 2015. 29(4):717-26
3. Baldini EH, Abrams RA, Bosch W, Roberge D, Haas RL, Catton CN, Indelicato DJ, **Olsen JR**, Deville C, Chen YL, Finkelstein SE, DeLaney TF, Wang D. Retroperitoneal Sarcoma Target Volume and Organ at Risk Contour Delineation Agreement Among NRG Sarcoma Radiation Oncologists. International Journal of Radiation Oncology Biology Physics, 2015: 92(5):1053-9.
4. Dyk P, Badiyan SN, Myerson RJ, Parikh PJ, **Olsen JR\***. The effect of high-dose sterotactic body radiation therapy on liver function in the treatment of primary and metastatic liver malignancies utilizing the Child-Pugh Score Classification System. Practical Radiation Oncology, 2015. 5(3):176-82.
5. Hu Y, Zhao W, Du D, Wooten HO, **Olsen JR**, Gay HA, Michalski JM, Mutic S. Magnetic resonance imaging-based treatment planning for prostate cancer: Use of population average tissue densities within the irradiated volume to improve plan accuracy. Practical Radiation Oncology, 2015; 5(4):248-56.
6. Wooten HO, Green O, Yang M, DeWees T, Kashani R, **Olsen JR**, Michalski J, Yang D, Tanderup K, Hu Y, Li HH, Mutic S. Quality of Intensity Modulated Radiation Therapy Treatment Plans Using a (60)Co Magnetic Resonance Image Guidance Radiation Therapy System. International Journal of Radiation Oncology Biology Physics, 2015: 92(4):771-8.
7. Pepin E, Olsen L, Badiyan S, Murad F, Mullady D, Wang-Gillam A, Linehan D, Parikh PJ, **Olsen JR\***. Comparison of implanted fiducial markers and metallic biliary stent for pancreatic IGRT localization. Practical Radiation Oncology, 2015. 5(3)e193-9.
8. Dad L, Shah M, Mutter RW, **Olsen JR**, Dominello M, Miller S, Fisher B, Lee NY, Komaki R. 4-year report (2009-2013) of the Association of Residents in Radiation Oncology (ARRO) Global Health Initiative GHI). International Journal of Radiation Oncology Biology Physics, July 2014: 89(3):485-91.
9. Myerson RJ, Tan B, Hunt S, **Olsen JR**, Birnbaum E, Fleshman J, Gao F, Hall L, Kodner I, Lockhart AC, Mutch M, Naughton M, Picus J, Rigden C, Safar B, Sorscher S, Suresh R, Wang-Gillam A, Parikh PJ. Five fractions of radiotherapy followed by four cycles of FOLFOX chemotherapy as preoperative treatment for rectal cancer. International Journal of Radiation Oncology\*Biology\*Physics, March 2014: 88(4): 829-36.
10. Robinson CG, DeWees TA, El Naqa IM, Creach KM, **Olsen JR**, Crabtree TD, Meyers BF, Puri V, Bell JM, Parikh PJ, Bradley JD. Patterns of failure after stereotactic body radiation therapy or lobar resection for clinical stage I non-small-cell lung cancer. Journal of Thoracic Oncology, 2013; 8(2):192-201.
11. Badiyan SN, **Olsen JR**\*, Lee AY, Yano M, Menias CO, Khwaja S, Wang-Gillam A, Strasberg SM, Hawkins WG, Linehan DC, Myerson RJ, Parikh PJ. Induction Chemotherapy Followed by Concurrent Full-Dose Gemcitabine and Intensity-Modulated Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma. American Journal of Clinical Oncology, Epub, November 2013.
12. **Olsen JR\***, Michalski JM. PSA screening for colorectal cancer patients: proceeding with caution. Oncology, October 2013; 27(10):1041-2.
13. **Olsen JR\***,Esthappan J, DeWees T, Narra VR, Dehdashti F, Siegel BA, Schwarz JK, Grigsby PW. Tumor volume and subvolume concordance between FDG-PET/CT and diffusion-weighted MRI for squamous cell carcinoma of the cervix. Journal of Magnetic Resonance Imaging, February 2013; 37(2):431-4. Epub. September 2012. [PMCID: PMC3541467]
14. Badiyan S, Bierhals AJ, **Olsen JR**, Creach KM, Garsa AA, Dewees T, Bradley JD, Robinson CG. Stereotactic body radiation therapy for the treatment of early-stage minimally invasive adenocarcinoma or adenocarcinoma in situ (formerly bronchioloalveolar carcinoma). Radiation Oncology, January 2013;8:4. [PMCID: PMC3552761]
15. Creach KM, El Naqa I, Bradley JD, **Olsen JR**, Parikh PJ, Drzymala RE, Bloch C, Robinson CG. Dosimetric Predictors of chest wall pain after lung stereotactic body radiotherapy. Radiotherapy + Oncology, 2012;104(1):199-204. Epub March 2012.
16. **Olsen JR**\*, Parikh PJ, Watts M, Noel, CE, Baker, KW, Santanam L, Michalski JM. Comparison of dose decrement from intrafraction motion for prone and supine prostate radiotherapy. Radiotherapy + Oncology, 2012:104(2):199-204. Epub. July 2012. [PMCID: PMC3552761]
17. **Olsen JR\***, Parikh PJ, Watts M, Noel CE, Baker KW, Santanam L, Michalski JM. Comparison of dose decrement from intrafraction motion for prone and supine prostate radiotherapy. Radiotherapy + Oncology, 2012:104(2):199-204. [PMCID: PMC3423556]
18. **Olsen JR**\*, Noel C, Baker KW, Santanam L, Michalski J, Parikh PJ. A practical method of adaptive radiotherapy for prostate cancer using real-time electromagnetic tracking. International Journal of Radiation Oncology Biology Physics, 2012:82(5):1903-11. Epub. April 2011. [PMCID: PMC3132289]
19. **Olsen JR\***, Dehdashti F, Siegel BA, Zighelboim I, Grigsby PW, Schwarz JK. Prognostic utility of squamous cell carcinoma antigen in carcinoma of the cervix: association with pre- and posttreatment FDG-PET. International Journal of Radiation Oncology Biology Physics, 2011;81(3):234-47. Epub October 2010.
20. **Olsen JR**\*, Robinson CG, El Naqa I, Creach KM, Drzymala RE, Bloch C, Parikh PJ, Bradley JD. Dose-response for stereotactic body radiotherapy in early-stage non-small-cell lung cancer. International Journal of Radiation Oncology Biology Physics, 2011;81(4):e299-303. Epub April 2011.
21. Noel CE, Santanam L, **Olsen JR**, Baker KW, Parikh PJP. An automated method for adaptive radiation therapy for prostate cancer patients using continuous fiducial-based tracking. Physics in Medical Biology, 2010:55(1):65-82.
22. Esthappan J, Chaudhari S, Santanam L, Mutic S, **Olsen JR**, Macdonald DM, Low DA, Singh AK, Grigsby PW. Prospective clinical trial of positron emission tomography/computed tomography image-guided intensity-modulated radiation therapy for cervical carcinoma with positive para-aortic lymph nodes. International Journal of Radiation Oncology Biology Physics, 2008;72(4):1134-9.
23. **Olsen JR\***, Lu W, Hubenschmidt JP, Nystrom MM, Klahr P, Bradley JD, Low DA, Parikh PJ. Effect of Novel Amplitude/Phase Binning Algorithm on Commercial Four-Dimensional Computed Tomography Quality. International Journal of Radiation Oncology Biology Physics, 2008:70(1):243-52. Epub. November 2007. [PMCID: PMC2702992]
24. Martin MB, Sanders JM, Kendrick H, de Luca-Fradley K, Lewis JC, Van Brussel EM, **Olsen JR**, Meints GA, Burzynska A, Kafarski P, Croft SL, Oldfield E. Activity of bisphosphonates against Trypanosoma brucei rhodesiense. Journal of Medicinal Chemistry, 2002;45(14):2904-14.

**Grant Support**

***Completed Grants***

1. 3/2013-12/2015. PI: Olsen

**“**Pilot Study Of Gene Expression And Fdg-Pet/Mr Biomarkers For

Evaluation Of Response To Neoadjuvant Therapy For Locally Advanced Rectal Cancer”

Siteman Cancer Center Radiation Oncology Clinical Trials Grant.

Total Funding: $30,000

1. 8/2014-12/2015. PI: Olsen

“Prospective Phase I Study of nab-Paclitaxel plus Gemcitabine with Concurrent MR-Guided IMRT in Patients with Locally Advanced Pancreatic Cancer”

Siteman Cancer Center Radiation Oncology Clinical Trials Grant.

Total Funding: $25,000

1. 1/2015-12/2015. PI: Olsen

“Pilot Study of Online, Adaptive MRI-Guided SBRT for Unresectable Primary or Oligometastatic Central Thorax and Abdominal Malignancies”

Viewray, Inc Clinical Trial Sponsorship Award

Total Approved Funding: $103,697

1. 8/2015-12/2015. PI: Olsen

“Pilot Study of Five Fractions of Radiotherapy Followed by FOLFOX/CAPEOX Chemotherapy as Organ Sparing Treatment for Low Risk Rectal Cancer”

Total Funding: $32,000

1. 12/2014 – 10/30/2014 PI: Olsen

“Evaluation of treatment outcomes using VISICOIL fiducial markers for highly conformal pancreatic cancer radiotherapy”.

Radiomed, Inc Research Support

Total Funding: $30,000

**Prospective Clinical Trials**

***Single Institution, Investigator Initiated***

1. Prospective Phase I Study of nab-Paclitaxel plus Gemcitabine with Concurrent MR-Guided IMRT in Patients with Locally Advanced Pancreatic Cancer. 1/21/15 – Ongoing.

PI: Olsen (Parikh upon departure from Washington University)

1. Pilot Study of Online, Adaptive MRI-Guided SBRT for Unresectable Primary or Oligometastatic Central Thorax and Abdominal Malignancies. 1/13/15-Ongoing.

PI: Olsen (Parikh upon departure from Washington University)

1. Pilot Study of Gene Expression and FDG-PET/MR Biomarkers for Evaluation of Response to Neoadjuvant Therapy for Locally Advanced Rectal Cancer. 6/25/14-Ongoing.
PI: Olsen (Parikh upon departure from Washington University)

***Multi-Institutional***

1. A Phase II Study Evaluating The Efficacy and Safety of Ultratrace Iobenguane 131 in Patients with Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma. 6/11/14-Ongoing.

Multi-Institutional, Industry sponsored

Institutional PI: Olsen (Perkins upon departure from Washington University)

**Book Chapters:**

1. **Olsen JR**, Kachnic LA. “When should postoperative radiochemotherapy be performed?” in: *Multidisciplinary Management of Rectal Cancer – Questions and Answers*. 2nd ed. Springer; 2015.
2. Benson AB, **Olsen JR**, Sasson AR. “Pancreatic, Neuroendocrine GI, and Adrenal Cancers.” Cancer Management: A Multidisciplinary Approach, 14th ed. Eds. Pazur R, Wagman LD, Camphausen KA, Hoskins WJ. UBM Medica; 2012.
3. **Olsen JR\***, Parikh PJ. “Calypso real-time localization and tracking for treatment of prostate cancer with external beam radiotherapy.” in: *Image Guided Radiation Therapy (IGRT): A clinical perspective. 1st ed*. New York: McGraw-Hill; 2011.

**Published Abstracts:**

1. Pryma D, Jimenez C, Chin B, **Olsen JR**, Pampaloni M, Solnes L, Stubbs J, Armor T, Jensen J, Wong V. Preliminary dosimetry results from a phase II study evaluating the efficacy and safety of Ultratrace® iobenguane I131 in patients with relapsed/refractory malignant pheochromocytoma/paragamglioma. Oral presentation EANM 2015.
2. Jimenez C, Chin B, **Olsen JR**, Pampaloni MH, Solnes LB, Dillon J, Stambler N, Armor T, Jensen J, Israel R, Wong V, Pryma DA. “A Pivotal Phase 2 Study of Ultratrace Iobenguane I-131 (Azedra) in Patients with Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma”. ASCO 2015.
3. **Olsen JR**, Moughan J, Myerson RJ, Abitbol A, Kunos C, Johnson D, Schefter T, Chen Y, Fischer B, Michalski J, Narayan S, Chang A, Crane C, Kachnic L. Predictors of Radiotherapy-Related GI Toxicity from Anal Cancer DP-IMRT: Secondary Analysis of

RTOG 0529. Accepted for oral presentation, ASTRO 2014.

1. McClain B, **Olsen JR**, Green O, Yang D, Santanam L, Olsen L, Zhao T, Rodriguez V, Wooten H, Mutic S, Victoria J, Dempsey J, Kashani R. Sensitivity of Plan Re-Optimization to Errors in Deformable Image Registration in Online Adaptive Image-Guided Radiation Therapy. Medical Physics, 2015: 42(6):3654.
2. Buchwald Z, Badiyan S, DeWees T, Hu Y, Fields R, Wang-GIllam A, **Olsen JR**. “Pretreatment diffusion weighted imaging for clinical outcome assessment in patients undergoing definitive chemoradiation for pancreatic adenocarcinoma.” ASCO GI Symposium 2015, San Francisco, CA.
3. Baldini EH, Bosch W, Abrams RA, Roberge D, **Olsen JR**, Haas RL, Catton CN, Indelicato DJ, DeLaney TF, Wang D. Retroperitoneal Sarcoma (RPS) Target Volume and Organ at Risk (OAR) Contour Delineation Agreement Among RTOG Sarcoma Radiation Oncologists. Accepted for oral presentation, ASTRO 2014.
4. Dyk PT, Parikh PJ, **Olsen JR**. Analysis of Abdominal and Chest Wall Toxicity Following Liver SBRT. International Journal of Radiation Oncology Biology Physics, 2013;84(3):S327.
5. Speirs CK, Benegal A, Fowler KJ, **Olsen JR**, Saad N, Sharma A, Garcia-Ramirez J, R. Laforest, Parikh PJ. 90Y Microsphere Hepatic Distribution Can Be Evaluated Following Radioembolization With PET/MRI. International Journal of Radiation Oncology Biology Physics, 2013;84(3):S320.
6. **Olsen JR**, Parikh PJ, Hunt S, Tan B, Myerson RJ. Sequential Short Course Radiation and FOLFOX as Preoperative Therapy for Rectal Cancer: Favorable LC, PFS, and QOL at 2 Years. International Journal of Radiation Oncology Biology Physics, 2013;84(3):S88.
7. Du D, Wooten HO, Feng Y, **Olsen JR**, Mutic S, Hu Y. Patient-Specific Bulk Electron Density Overridden Planning for Prostate and Brain Cancer. Medical Physics, 2013;40(6):192.
8. Du D, Green OL, Feng Y, Mutic S, Parikh PJ, **Olsen JR**, Hu Y. Employing Compressed Sensing to Improve Tracking Image Quality of the MRI-Guided Radiotherapy System. Medical Physics, 2013;40(6):94.
9. Hu Y, Zhao W, Du D, Wooten HO, **Olsen JR**, Gay HA, Michalski JM, Mutic S. Improved Dosimetric Accuracy of Bulk Density Overridden Plans for Prostate Patients Using Tissue Population Average Electron Densities Obtained Within Radiation Beam Paths. International Journal of Radiation Oncology Biology Physics , 2013;87(2):S720.
10. Hu Y, Green OL, Y. Feng, Du D, Wooten HO, Li HH, Santanam L, Parikh PJ, **Olsen JR**, Mutic S. Image Performance Characterization of an MRI-Guided Radiation Therapy System. International Journal of Radiation Oncology Biology Physics , 2013;87(2):S13.
11. Appenzoller LM, **Olsen JR**, Mutic S, Moore KL. Applicability of a General Predictive DVH (pDVH) Model to Rare Treatment Sites With No Prior Training Data. International Journal of Radiation Oncology Biology Physics, 2013;87(2):S623.
12. Hu Y, Green OL, Parikh PJ, **Olsen JR**, Mutic S. Initial experience with the ViewRay system – quality assurance testing of the imaging component. Medical Physics, 2012;39:4013.
13. **Olsen JR**, Noel CE, Spencer CR, Green OL, Hu Y, Mutic S, Parikh PJ. Feasibility of single and multiplane cine MR for monitoring tumor volumes and organs-at-risk (OARs) position during radiation therapy. International Journal of Radiation Oncology Biology Physics, 2012;84(3):S742.
14. DeWees TA, Creach KM, **Olsen JR**, Bradley JD, Robinson CG. Defining optimal comorbidity measures for patients with medically inoperable early-stage non-small cell lung cancer (NSCLC) treated with stereotactic body radiation therapy (SBRT). International Journal of Radiation Oncology Biology Physics, 2012;84(3):S172.
15. Parikh PJ, Noel CE, Spencer CR, Green OL, Hu Y, Mutic S, **Olsen JR**. Comparison of onboard low-field MRT versus CBCT/MVCT for anatomy identification in radiation therapy. International Journal of Radiation Oncology Biology Physics, 2012;84(3):S133.
16. Green OL, Hu Y, Noel CE, **Olsen JR**, Mutic S. Observation of radiation-induced tissue signal intensity changes with the first commercial MRI-guided IMRT system. International Journal of Radiation Oncology Biology Physics, 2012;84(3):S758-S759.
17. Badiyan S, Bierhals AJ, **Olsen JR**, Creach KM, Garsa AA, DeWees T, Bradley JD, Robinson CG. Stereotactic body radation therapy for the treatment of early-stage bronchoalveolar carcinoma: a patterns of failure analysis. International Journal of Radiation Oncology Biology Physics, 2011; 81(2):S584.
18. **Olsen JR**\*, DeWees T, Schwarz JK, Grigsby PW. Functional imaging concordance between FDG-PET and diffusion weighted MRI for carcinoma of the cervix. International Journal of Radiation Oncology Biology Physics, 2011;81(2):S456-7.
19. Kittel JA, **Olsen JR**, Schwarz JK, Powell MA, Mutch DG, Grigsby PW. Retrospective analysis of clinical outcomes of vaginal cancer patients. International Journal of Radiation Oncology Biology Physics, 2011;81(2):S481.
20. **Olsen JR**\*, Esthappan J, Hu Y, Schwarz JK, Grigsby PW. Changes in tumor diffusion measured by DWI during brachytherapy correlate with metabolic response on FDG-PET and progression free survival for SCC of the cervix. International Journal of Radiation Oncology Biology Physics, 2011;81(2):S188.
21. Mahowald GK, DeWees T, **Olsen JR**, Creach KM, Mullen D, Bradley JD, Robinson CG. Clinical and dosimetric factors predicting for radiation pneumonitis following lung SBRT. International Journal of Radiation Oncology Biology, 2011;81(2):S167.
22. Robinson CG, DeWees T, **Olsen JR**, Creach KM, Bradley JD. Patterns of failure and survival after SBRT for biopsy proven or radiographically diagnosed stage I NSCLC. International Journal of Radiation Oncology Biology Physics, 2011;81(2):S80.
23. **Olsen JR**\*, Robinson CG, El Naqa I, Creach KM, Drzymala RE, Bloch C, Parikh PJ, Bradley JD. Comparison of three treatment schemes for lung SBRT. International Journal of Radiation Oncology Biology, 2010;78(3):S182.
24. Noel CE, Higham-Kessler J, **Olsen JR**, Santanam L, Michalski J, Parikh PJ. Feasibility of fiducial-based electromagnetic tracking for postoperative radiotherapy to the prostate bed. International Journal of Radiation Oncology Biology Physics, 2010;78(3):S668-9.
25. Creach KM, Al-lozi R, El Naqa I, Bradley JD, **Olsen JR**, Parikh PJ, Drzymala RE, Bloch C, Robinson CG. Dosimetric prediction of chest wall toxicity after lung SBRT. International Journal of Radiation Oncology Biology Physics, 2010;78(3):S181-2.
26. **Olsen JR**, Noel CE, Baker K, Santanam L, Michalski JM, Parikh PJ. A practical method of adaptive radiotherapy for prostate cancer using real-time electromagnetic tracking. International Journal of Radiation Oncology Biology Physics, 2009; 75(5):S573.
27. Parikh PJ, **Olsen JR**, Smith RL, Noel CE, Khan D, Tropper S, Mantz C. Do interventions for prostate cancer intrafraction motion make a difference? International Journal of Radiation Oncology Biology Physics, 2009;75(3):S591.
28. **Olsen JR**\*, Noel CE, Santanam L, Michalski JM, Parikh PJ. Individual margin determination for prostate cancer patients undergoing real-time tracking. International Journal of Radiation Oncology Biology Physics, 2008;72(1):S574.
29. **Olsen JR**, Parikh PJ, Lu W, Hubenschmidt JP, Nystrom M, Klahr P, Bradley JD, Low DA. 99: The effect of a novel amplitude/phase binning algorithm on commercial 4DCT quality. International Journal of Radiation Oncology Biology Physics, 2006;66(3):S56-S57.